Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Medical experts proposed a radical overhaul of how obesity is diagnosed, moving away from relying on body mass alone and ...

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Some studies show that intermittent fasting may help maintain a healthy metabolism. When the body is in a fasted state, it ...